Short-chain fructooligosaccharides from sucrose and maintenance of normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: (Scientific Opinion)

Publikation: Bidrag til tidsskriftTidsskriftartikelRådgivningfagfællebedømt

Standard

Short-chain fructooligosaccharides from sucrose and maintenance of normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 : (Scientific Opinion). / EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA).

I: E F S A Journal, Bind 14, Nr. 1, 4366, 08.01.2016.

Publikation: Bidrag til tidsskriftTidsskriftartikelRådgivningfagfællebedømt

Harvard

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2016, 'Short-chain fructooligosaccharides from sucrose and maintenance of normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: (Scientific Opinion)', E F S A Journal, bind 14, nr. 1, 4366. https://doi.org/10.2903/j.efsa.2016.4366

APA

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) (2016). Short-chain fructooligosaccharides from sucrose and maintenance of normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: (Scientific Opinion). E F S A Journal, 14(1), [4366]. https://doi.org/10.2903/j.efsa.2016.4366

Vancouver

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Short-chain fructooligosaccharides from sucrose and maintenance of normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: (Scientific Opinion). E F S A Journal. 2016 jan. 8;14(1). 4366. https://doi.org/10.2903/j.efsa.2016.4366

Author

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). / Short-chain fructooligosaccharides from sucrose and maintenance of normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 : (Scientific Opinion). I: E F S A Journal. 2016 ; Bind 14, Nr. 1.

Bibtex

@article{6e4af350af5045bd947a5b98d58279d9,
title = "Short-chain fructooligosaccharides from sucrose and maintenance of normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: (Scientific Opinion)",
abstract = "Following an application from Beghin-Meiji and Tereos Syral, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) was asked to deliver an opinion on the scientific substantiation of a health claim related to short-chainfructooligosaccharides (scFOS) from sucrose and maintenance of normal defecation. The food constituent that is the subject of the health claim is scFOS from sucrose. The Panel considers that scFOS from sucrose is sufficiently characterised. The claimed effect proposed by the applicant is {\textquoteleft}maintaining normal intestinal transit regularity by increasing stool frequency{\textquoteright}. The target population proposed by the applicant is the general population. Upon a request from EFSA, the applicant confirmed that the proposed claimed effect refers to maintenance of normal defecation. The Panel considers that maintenance of normal defecation is a beneficial physiological effect. The Panel considers that one human intervention study did not show an effect of scFOS from sucrose at a dose of 5.7 g/day for 4 weeks on defecation frequency, consistency of stools or dry faecal mass and that in two other human intervention studies 10 g/day of scFOS increased faecal bulk, whereas higher amounts (12.5 g/day) consumed for shorter period did not. Although a number of studies provided some evidence that scFOS are fermented in the colon and increase bacterial mass and faecal bulk, the information provided does not demonstrate that the changes in short-chain fatty acids (SCFA) or bile acids induced by scFOS lead to significant changes in the frequency of stools. The Panel concludes that a cause and effect relationship has not been established between the consumption of scFOS fromsucrose and maintenance of normal defecation under proposed conditions of use. ",
keywords = "Faculty of Science, Short-chain fructooligosaccharides from sucrose, Defecation, Bowel function, Constipation, Health claim",
author = "{EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)} and Sj{\"o}din, {Anders Mikael}",
note = "EFSA 2016 4366",
year = "2016",
month = jan,
day = "8",
doi = "10.2903/j.efsa.2016.4366",
language = "English",
volume = "14",
journal = "E F S A Journal",
issn = "1831-4732",
publisher = "European Food Safety Authority (E F S A)",
number = "1",

}

RIS

TY - JOUR

T1 - Short-chain fructooligosaccharides from sucrose and maintenance of normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

T2 - (Scientific Opinion)

AU - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

AU - Sjödin, Anders Mikael

N1 - EFSA 2016 4366

PY - 2016/1/8

Y1 - 2016/1/8

N2 - Following an application from Beghin-Meiji and Tereos Syral, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) was asked to deliver an opinion on the scientific substantiation of a health claim related to short-chainfructooligosaccharides (scFOS) from sucrose and maintenance of normal defecation. The food constituent that is the subject of the health claim is scFOS from sucrose. The Panel considers that scFOS from sucrose is sufficiently characterised. The claimed effect proposed by the applicant is ‘maintaining normal intestinal transit regularity by increasing stool frequency’. The target population proposed by the applicant is the general population. Upon a request from EFSA, the applicant confirmed that the proposed claimed effect refers to maintenance of normal defecation. The Panel considers that maintenance of normal defecation is a beneficial physiological effect. The Panel considers that one human intervention study did not show an effect of scFOS from sucrose at a dose of 5.7 g/day for 4 weeks on defecation frequency, consistency of stools or dry faecal mass and that in two other human intervention studies 10 g/day of scFOS increased faecal bulk, whereas higher amounts (12.5 g/day) consumed for shorter period did not. Although a number of studies provided some evidence that scFOS are fermented in the colon and increase bacterial mass and faecal bulk, the information provided does not demonstrate that the changes in short-chain fatty acids (SCFA) or bile acids induced by scFOS lead to significant changes in the frequency of stools. The Panel concludes that a cause and effect relationship has not been established between the consumption of scFOS fromsucrose and maintenance of normal defecation under proposed conditions of use.

AB - Following an application from Beghin-Meiji and Tereos Syral, submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) was asked to deliver an opinion on the scientific substantiation of a health claim related to short-chainfructooligosaccharides (scFOS) from sucrose and maintenance of normal defecation. The food constituent that is the subject of the health claim is scFOS from sucrose. The Panel considers that scFOS from sucrose is sufficiently characterised. The claimed effect proposed by the applicant is ‘maintaining normal intestinal transit regularity by increasing stool frequency’. The target population proposed by the applicant is the general population. Upon a request from EFSA, the applicant confirmed that the proposed claimed effect refers to maintenance of normal defecation. The Panel considers that maintenance of normal defecation is a beneficial physiological effect. The Panel considers that one human intervention study did not show an effect of scFOS from sucrose at a dose of 5.7 g/day for 4 weeks on defecation frequency, consistency of stools or dry faecal mass and that in two other human intervention studies 10 g/day of scFOS increased faecal bulk, whereas higher amounts (12.5 g/day) consumed for shorter period did not. Although a number of studies provided some evidence that scFOS are fermented in the colon and increase bacterial mass and faecal bulk, the information provided does not demonstrate that the changes in short-chain fatty acids (SCFA) or bile acids induced by scFOS lead to significant changes in the frequency of stools. The Panel concludes that a cause and effect relationship has not been established between the consumption of scFOS fromsucrose and maintenance of normal defecation under proposed conditions of use.

KW - Faculty of Science

KW - Short-chain fructooligosaccharides from sucrose

KW - Defecation

KW - Bowel function

KW - Constipation

KW - Health claim

U2 - 10.2903/j.efsa.2016.4366

DO - 10.2903/j.efsa.2016.4366

M3 - Journal article

VL - 14

JO - E F S A Journal

JF - E F S A Journal

SN - 1831-4732

IS - 1

M1 - 4366

ER -

ID: 187623875